Cargando…

Follow up after IMRT in oral cavity cancer: update

PURPOSE: Except for early stages (T1/2 N0), the prognosis for patients with oral cavity cancer (OCC) is known to be worse than for those with pharyngeal carcinoma. While definitive intensity modulated radiation therapy (IMRT)-chemotherapy affords loco-regional control rates (LRC) of approximately 80...

Descripción completa

Detalles Bibliográficos
Autores principales: Studer, Gabriela, Brown, Michelle, Bredell, Marius, Graetz, Klaus W, Huber, Gerhard, Linsenmeier, Claudia, Najafi, Yousef, Riesterer, Oliver, Rordorf, Tamara, Schmid, Stephan, Glanzmann, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488022/
https://www.ncbi.nlm.nih.gov/pubmed/22686297
http://dx.doi.org/10.1186/1748-717X-7-84
_version_ 1782248568346640384
author Studer, Gabriela
Brown, Michelle
Bredell, Marius
Graetz, Klaus W
Huber, Gerhard
Linsenmeier, Claudia
Najafi, Yousef
Riesterer, Oliver
Rordorf, Tamara
Schmid, Stephan
Glanzmann, Christoph
author_facet Studer, Gabriela
Brown, Michelle
Bredell, Marius
Graetz, Klaus W
Huber, Gerhard
Linsenmeier, Claudia
Najafi, Yousef
Riesterer, Oliver
Rordorf, Tamara
Schmid, Stephan
Glanzmann, Christoph
author_sort Studer, Gabriela
collection PubMed
description PURPOSE: Except for early stages (T1/2 N0), the prognosis for patients with oral cavity cancer (OCC) is known to be worse than for those with pharyngeal carcinoma. While definitive intensity modulated radiation therapy (IMRT)-chemotherapy affords loco-regional control rates (LRC) of approximately 80% in advanced pharyngeal cancer, corresponding rates are reported to be much lower for OCC. The aim of this work was to evaluate loco-regional disease control and overall survival (OAS) in a relatively large OCC patient cohort treated in the IMRT era. METHODS AND MATERIALS: Between October 2002 and June 2011, 160 OCC patients were treated with curative intention IMRT at our department. 122 patients (76%) were referred with primary disease and 38 patients (24%) with a recurrent OCC at least 3 months after surgery alone. Definitive IMRT was performed in 44/160 patients (28%), whilst 116 patients underwent previous surgery. Simultaneous systemic therapy was administered in 72%. RESULTS: Patients with postoperative IMRT (+/−systemic therapy) with R0-1 status (n = 99) reached significantly higher LRC/OAS rates than patients following IMRT for macroscopic disease (n = 61), with 84%/80% versus 38%/33% at 3 years, respectively (p < 0.0001). This was found in patients treated for initial, as well as recurrent, disease. Less than 2% persisting grade 3/4 late effects were observed. CONCLUSIONS: IMRT for R0-1 situations translated into a highly significant superior LRC and OAS compared to the IMRT cohort treated for macroscopic disease. Treatment was well tolerated.
format Online
Article
Text
id pubmed-3488022
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34880222012-11-03 Follow up after IMRT in oral cavity cancer: update Studer, Gabriela Brown, Michelle Bredell, Marius Graetz, Klaus W Huber, Gerhard Linsenmeier, Claudia Najafi, Yousef Riesterer, Oliver Rordorf, Tamara Schmid, Stephan Glanzmann, Christoph Radiat Oncol Research PURPOSE: Except for early stages (T1/2 N0), the prognosis for patients with oral cavity cancer (OCC) is known to be worse than for those with pharyngeal carcinoma. While definitive intensity modulated radiation therapy (IMRT)-chemotherapy affords loco-regional control rates (LRC) of approximately 80% in advanced pharyngeal cancer, corresponding rates are reported to be much lower for OCC. The aim of this work was to evaluate loco-regional disease control and overall survival (OAS) in a relatively large OCC patient cohort treated in the IMRT era. METHODS AND MATERIALS: Between October 2002 and June 2011, 160 OCC patients were treated with curative intention IMRT at our department. 122 patients (76%) were referred with primary disease and 38 patients (24%) with a recurrent OCC at least 3 months after surgery alone. Definitive IMRT was performed in 44/160 patients (28%), whilst 116 patients underwent previous surgery. Simultaneous systemic therapy was administered in 72%. RESULTS: Patients with postoperative IMRT (+/−systemic therapy) with R0-1 status (n = 99) reached significantly higher LRC/OAS rates than patients following IMRT for macroscopic disease (n = 61), with 84%/80% versus 38%/33% at 3 years, respectively (p < 0.0001). This was found in patients treated for initial, as well as recurrent, disease. Less than 2% persisting grade 3/4 late effects were observed. CONCLUSIONS: IMRT for R0-1 situations translated into a highly significant superior LRC and OAS compared to the IMRT cohort treated for macroscopic disease. Treatment was well tolerated. BioMed Central 2012-06-11 /pmc/articles/PMC3488022/ /pubmed/22686297 http://dx.doi.org/10.1186/1748-717X-7-84 Text en Copyright ©2012 Studer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Studer, Gabriela
Brown, Michelle
Bredell, Marius
Graetz, Klaus W
Huber, Gerhard
Linsenmeier, Claudia
Najafi, Yousef
Riesterer, Oliver
Rordorf, Tamara
Schmid, Stephan
Glanzmann, Christoph
Follow up after IMRT in oral cavity cancer: update
title Follow up after IMRT in oral cavity cancer: update
title_full Follow up after IMRT in oral cavity cancer: update
title_fullStr Follow up after IMRT in oral cavity cancer: update
title_full_unstemmed Follow up after IMRT in oral cavity cancer: update
title_short Follow up after IMRT in oral cavity cancer: update
title_sort follow up after imrt in oral cavity cancer: update
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488022/
https://www.ncbi.nlm.nih.gov/pubmed/22686297
http://dx.doi.org/10.1186/1748-717X-7-84
work_keys_str_mv AT studergabriela followupafterimrtinoralcavitycancerupdate
AT brownmichelle followupafterimrtinoralcavitycancerupdate
AT bredellmarius followupafterimrtinoralcavitycancerupdate
AT graetzklausw followupafterimrtinoralcavitycancerupdate
AT hubergerhard followupafterimrtinoralcavitycancerupdate
AT linsenmeierclaudia followupafterimrtinoralcavitycancerupdate
AT najafiyousef followupafterimrtinoralcavitycancerupdate
AT riestereroliver followupafterimrtinoralcavitycancerupdate
AT rordorftamara followupafterimrtinoralcavitycancerupdate
AT schmidstephan followupafterimrtinoralcavitycancerupdate
AT glanzmannchristoph followupafterimrtinoralcavitycancerupdate